Suzhou Ribo Life Science Company — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

A Chinese leader in RNA interference (RNAi) therapeutics for cancer and genetic diseases.

OncologyGenetics & Genomics

Proprietary RNA interference (RNAi) platform with advanced delivery technologies for systemic targeting of disease-causing genes.

Potential to leverage its RNAi platform to form multiple discovery and development partnerships across various disease areas.

Platform risk associated with the clinical validation of its delivery technology and potential for off-target effects or immune reactions.

A domestic leader in RNAi but faces competition from global giants with more advanced clinical and commercial RNAi portfolios.